NMPA Approves the NDA for CARsgen’s BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma
CARsgen Therapeutics Holdings Limited announces that today the National Medical Products Administration (“NMPA”) of China has approved the New Drug Application (“NDA”) for zevorcabtagene autoleucel.
